Preferred Label : Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01;
NCIt synonyms : Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic VV RIVAL-01; Engineered Oncolytic Vaccinia Virus TBio-6517;
NCIt definition : An oncolytic vaccinia virus (VV; VACV) genetically engineered to express an Fms-like
tyrosine kinase 3 (Flt3) ligand, an antibody directed against the human T-cell-expressed
receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the human pro-inflammatory
cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic
activities. Upon administration of the Flt3 ligand/anti-CTLA-4 antibody/IL-12 engineered
oncolytic VV RIVAL-01, the virus preferentially targets, infects and replicates in
tumor cells, causing oncolysis. In turn, the lysed tumor cells release various tumor-associated
antigens (TAAs), which induce an immune response against the tumor cells. In addition,
the Flt3 ligand, the anti-ctla-4 antibody and IL-12 are expressed by the VV in the
cancer cells and may activate the immune system within the tumor microenvironment
(TME), thereby stimulating both innate and adaptive immune responses. The anti-CTLA-4
antibody targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated
downregulation of T-cell activation, which promotes T-cell activation. Flt3 ligand
binds to the Flt3 tyrosine kinase receptor and promotes Flt3 signaling which plays
an important role in expanding the population of antigen-presenting dendritic cells
(DCs). IL-12 activates natural killer cells (NKs), induces the secretion of interferon-gamma
and promotes CD8 cytotoxic T-cell responses against tumor cells, which may result
in immune-mediated tumor cell death and inhibition of tumor cell proliferation.;
Molecule name : TBio 6517; RIVAL-01; TAK-605; TBio-6517; RIVAL 01;
NCI Metathesaurus CUI : CL1407953;
Origin ID : C174049;
UMLS CUI : C5418058;
Semantic type(s)
- Virus [UMLS semantic type]
- concept_is_in_subset
